Home Top healthcare stock fund focuses on costs, orphan drugs in 2016
 

Keywords :   


Top healthcare stock fund focuses on costs, orphan drugs in 2016

2015-11-18 01:43:18| Biotech - Topix.net

Healthcare companies that can either contain costs or develop medications to treat rare diseases, known as orphan drugs, will be the most likely to outperform in the coming year, said John Fraunces, whose Turner Medical Sciences Long/Short fund is among the top performing healthcare funds over the last 5 years. Fraunces, who co-manages the $134 million fund, said he has been increasing his short positions, or bets that shares will decline, on companies that face increased price pressure for high-priced drugs.

Tags: top stock costs fund

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
26.06Horizon expert 'gave evidence based on informal chats'
26.06Automotive Color by BASF Recognized with Renowned Red Dot Award
26.06Beckers Commits to Widespread Science Based Targets
26.06PPG to Announce Second-quarter 2024 Results July 18
26.06Fresh Coat for First Responders: New Hampshire Fire Station Gets a Makeover by California Paints
26.06Michigan Sets Record Recycling Rate in 2023, Recycles Nearly 70,000 Tons of Materials
26.06Companies Seek Federal EPR: How Producers Can Prepare
26.06Q&A with GFLs Tyler Stefure: Integrating New Fleet Tech & Upholding GFL Values
More »